LLY · Earnings call · 2026Q3T · Full report

Long-Acting Incretin Technology

ELI LILLY & Co · 2026-10-29 · Importance 26 · Surprise 30

Lilly sees an opportunity for longer-acting incretins, particularly in a large category with substantial consumer involvement. Management said it is evaluating multiple clinical efforts using different technological approaches, including existing time-extension technologies and potential future approaches. The company is also considering formulation programs disclosed through business development. Lilly expects to assess the data and decide which approach or approaches to advance to Phase 3.